Inducción a buprenorfina sublingual desde metadona: estudio clínico descriptivo en una muestra de pacientes tratados en una comunidad terapéutica

González‐Sáiz, Francisco; Ortega, Josefa Gutiérrez; Acedos, Izaskun Bilbao; Gómez, Rosario Ballesta; Lozano, Óscar

doi:10.1016/s1575-0973(08)74546-x

Cited by 4 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eighteen studies (reported in 19 articles) transferred patients from methadone to buprenorphine, with a total of 382 patients enrolled 21–39 . Eight studies were conducted in the United States, 6 in Europe, and 4 in Australasia.…”

Section: Resultsmentioning

confidence: 99%

“…Seven studies reported retention in treatment for at least 2 months after transfer 28–32,34,39 . Retention rates ranged from 40% to 73% during follow-up periods ranging from 2 to 30 months.…”

Section: Resultsmentioning

confidence: 99%

“…In another study, the initial buprenorphine dose was administered via a transdermal patch that delivered 35 μg/h 34 . The remaining studies allowed the initial dose on the first day to vary 22,24,30,32,33,36 …”

Section: Resultsmentioning

confidence: 99%

“…35,37 Seven studies used a fixed or flexible methadone dose taper. 23,[25][26][27]30,32,36 In one of these studies, taper was offered to patients, but it is not reported whether any patients chose that strategy. 32 In another study, one of 3 groups was randomized to taper.…”

Section: Methadone Tapermentioning

confidence: 99%

“…The crude and weighted mean total buprenorphine doses on the first day were 8.6 and 7.8 mg, respectively. The lowest total first-day fixed dose was 2 mg, 21 and the lowest possible total first-day flexible-dose was 1 mg. 30 The highest initial fixed or flexible total daily dose on the first day was 32 mg. 29,37…”

Section: Total First-day Dose Of Buprenorphinementioning

confidence: 99%

See 4 more Smart Citations

Strategies for Transfer From Methadone to Buprenorphine for Treatment of Opioid Use Disorders and Associated Outcomes: A Systematic Review

Lintzeris

Mankabady

Rojas‐Fernandez

et al. 2021

Journal of Addiction Medicine

View full text Add to dashboard Cite

Objectives: To review the currently available evidence on transfer strategies from methadone to sublingual buprenorphine used in clinical trials and observational studies of medication for opioid use disorder treatment, and to consider whether any strategies yield better clinical outcomes than others. Methods: Six medical and public health databases were searched for articles and conference abstracts. The Cochrane Central Register of Controlled Trials and the World Health Organization International Clinical Trials Registry Platform were used to identify unpublished trial results. Records were dually screened, and data were extracted and checked independently. Results were summarized qualitatively and, when possible, analyzed quantitatively. Results: Eighteen studies described transfer from methadone to buprenorphine. Transfer protocols were extremely varied. Most studies reported successful rates of transfer, even among studies involving transfer from high methadone doses, although lower pretransfer methadone dose was significantly associated with higher rate of successful transfer. Precipitated withdrawal was not reported frequently. A range of innovative approaches to transfer from methadone to buprenorphine remains untested. Conclusions: Few studies have used designs that enable comparison of different approaches to transfer patients from methadone to buprenorphine. Most international clinical guidelines provide recommendations consistent with the available evidence. However, clinical guidelines should be perceived as providing ''guidance'' rather than ''protocols,'' and clinicians and patients need to exercise judgment when attempting transfers.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%